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Abstract Nucleotides and nucleosides are not only in-
volved in cellular metabolism but also act extracellularly
via P1 and P2 receptors, to elicit a wide variety of physio-
logical and pathophysiological responses through paracrine
and autocrine signalling pathways. For the first time, we
have used an ion-pair reversed-phase high-performance liq-
uid chromatography ultraviolet (UV)-coupled method to
rapidly and simultaneously quantify 12 different nucleotides
and nucleosides (adenosine triphosphate, adenosine diphos-
phate, adenosine monophosphate, adenosine, uridine tri-
phosphate, uridine diphosphate, uridine monophosphate,
uridine, guanosine triphosphate, guanosine diphosphate,
guanosine monophosphate, guanosine): (1) released from a
mouse renal cell line (M1 cortical collecting duct) and (2) in
human biological samples (i.e., urine). To facilitate analysis
of urine samples, a solid-phase extraction step was incorpo-
rated (overall recovery rate ≥98 %). All samples were ana-
lyzed following injection (100 μl) into a Synergi Polar-RP
80 Å (250×4.6 mm) reversed-phase column with a particle
size of 10 μm, protected with a guard column. A gradient
elution profile was run with a mobile phase (phosphate
buffer plus ion-pairing agent tetrabutylammonium hydrogen
sulfate; pH 6) in 2–30 % acetonitrile (v/v) for 35 min (in-
cluding equilibration time) at 1 ml min−1 flow rate. Eluted
compounds were detected by UVabsorbance at 254 nm and
quantified using standard curves for nucleotide and nucleo-
side mixtures of known concentration. Following validation
(specificity, linearity, limits of detection and quantitation,
system precision, accuracy, and intermediate precision
parameters), this protocol was successfully and reproducibly
used to quantify picomolar to nanomolar concentrations of
nucleosides and nucleotides in isotonic and hypotonic cell
buffers that transiently bathed M1 cells, and urine samples
from normal subjects and overactive bladder patients.
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Introduction
Extracellular nucleotides and nucleosides are released by
most mammalian cells following mechanical and chemical
stimuli, and in response to pathophysiological states such as
Alberto Contreras-Sanz and Toby S. Scott-Ward contributed equally.
Electronic supplementary material The online version of this article
(doi:10.1007/s11302-012-9321-8) contains supplementary material,
which is available to authorized users.
A. Contreras-Sanz :H. S. Gill :K. M. G. Taylor
Department of Pharmaceutics, UCL School of Pharmacy,
London WC1N 1AX, UK
T. S. Scott-Ward (*) : R. E. Birch : C. M. Peppiatt-Wildman :
S. S. P. Wildman (*)
Medway School of Pharmacy,
The Universities of Kent and Greenwich at Medway,
Chatham Maritime,




Faculty of Life Sciences, London Metropolitan University,
London N7 8DB, UK
J. Malone-Lee
Research Centre for Clinical Science and Technology, UCL,
London N19 5LW, UK
Purinergic Signalling (2012) 8:741–751
DOI 10.1007/s11302-012-9321-8
inflammation and hypoxia [1]. Although numerous release
mechanisms have been proposed to date [2, 3], these have
proved challenging to define due to technical problems
associated with quantifying nucleotide and nucleoside re-
lease. Once released, these molecules act at plasma
membrane-bound purinoceptors (P1R and P2R) to initiate
a sequence of downstream processes within the cell. The
P1R family comprises four receptor subtypes (A1, 2A, 2B,
3), whereas the P2R family is divided into seven P2X
subunits (P2X1–7) that form homo- or heteromeric ion
channels and eight P2Y subtypes (P2Y1, P2Y2, P2Y4,
P2Y6, and P2Y11–14), all G protein-coupled receptors [4].
Both P1R and P2R receptors are involved in a wide variety of
physiological and pathophysiological processes in multiple
organ systems ranging from digestion to neurotransmission,
smooth muscle contraction, immune response, inflammation,
and pain sensation [5]. Moreover, extracellular nucleotide and
nucleoside signalling plays a key regulatory role in the kidney,
especially in renal collecting duct tubular transport, and in
regulating the medullary microcirculation [6–8].
In the bladder, nucleotides and nucleosides play an
important role in sensing bladder filling and the ensuing
detrusor muscle contraction that determines bladder voiding
[9]. Interestingly, altered nucleotide and nucleoside signal-
ling is thought to underlie pathological conditions of the
bladder, such as overactive bladder (OAB) [10–12], inter-
stitial cystitis [13, 14], and benign prostatic hyperplasia
[10]. To date, the majority of studies have focused on the
actions of adenosine (Ado) and adenosine triphosphate
(ATP) on P1Rs and P2Rs, respectively, with little attention
to other extracellular nucleotides or nucleosides. This is
most likely due to due to the lack of appropriate assays to
assess their concentration and/or biological function. Given
that, like ATP and Ado, many of these other molecules are
similarly degraded by endogenous ectonucleotidases and
also exert their effect following binding to P1Rs and P2Rs
[15–17], it is also important to investigate their extracellular
concentration in model cell culture systems and biological
samples such as blood and/or urine.
ATP concentration has historically been measured using
the established luciferin–luciferase luminescence assay
technique [18], which is highly sensitive and appropriate
for measuring localized ATP. However, alternative analyti-
cal methods exist, including chromatographic systems such
as high-performance liquid chromatography (HPLC)
attached to a UV detector (HPLC-UV) [19–21], or liquid
chromatography coupled to mass spectrometers (LC-MS)
[22–25]. While disparity continues between the concentra-
tion of ATP measured close to the cell surface and that in the
bulk extracellular phase, nanomolar or higher concentra-
tions of a range of extracellular nucleotides and nucleosides
have now been measured in a variety of systems including
cultured cells [22], isolated tissues [21], food substances
[20, 23, 24], fungi [25], and biological samples [19]. De-
spite this and recent studies describing ATP as a useful
biomarker for certain diseases [10–14], the importance of
other nucleotides and nucleosides remains largely unex-
plored, as indeed does their precise role in the physiology
or pathophysiology of other organs or systems. Simulta-
neous quantification of ATP, adenosine diphosphate
(ADP), adenosine monophosphate (AMP), Ado, guanosine
triphosphate (GTP), guanosine diphosphate (GDP), guano-
sine monophosphate (GMP), guanosine (Gua), uridine tri-
phosphate (UTP), uridine diphosphate (UDP), uridine
monophosphate (UMP), and uridine (Uri) cannot be per-
formed using the luciferin–luciferase assay, and, despite
their known biological function, quantification of extracel-
lular nucleotide/nucleoside concentrations in cell culture
buffers or urine samples using a HPLC-UV-coupled system
has yet to be reported.
The aim of this investigation was to develop a simple,
fast, reliable, and reproducible method for quantifying up to
12 different nucleotides and nucleosides in samples of vary-
ing complexity (i.e., cell buffers and human urine samples).
Specifically, we sought to determine whether differences in
nucleotide and nucleoside concentrations could be detected
between: (1) an isotonic and hypotonic buffer solution that
transiently bathed M1 cells and (2) urine samples from OAB
patients and non-OAB control subjects. The ion-pair
reversed-phase, UV-coupled HPLC method described here
was validated and successfully applied to quantify extracel-
lular nucleotide and nucleoside concentrations in the above
samples. This technique has the potential to be used not only
in studies of lower urinary tract function under normal and
disease states but also to assess changes in nucleotide and




ATP, ADP, AMP, Ado, GTP, GDP, GMP, Gua, UTP, UDP,
UMP, Uri, ethanolamine, phosphoric acid, tetrabutylammo-
nium hydrogen sulfate (TBAHS), K2HPO4, HClO4, NaCl,
KCl, CaCl2, MgCl2, NaHCO3, HEPES, orthophosphoric
acid, glucose, fetal bovine serum (FBS), penicillin/strepto-
mycin, and sodium selenite/insulin/transferrin/ethanolamine
were all obtained from Sigma-Aldrich (Poole, UK). HPLC-
grade acetonitrile (ACN) and methanol were obtained from
Fisher Scientific (Loughborough, UK). Dulbecco’s modi-
fied Eagle’s cell culture media (DMEM) was purchased
from Invitrogen (Paisley, UK). Creatinine was measured
using a modified Jaffe method (R&D Systems, Abingdon,
UK). Deionized water (dH2O) was produced in-house.
742 Purinergic Signalling (2012) 8:741–751
Apparatus and chromatographic conditions
The HPLC setup was formed of an Agilent 1200 series
autosampler (G1329A), column oven (G1316A), degasser
(G1379A), quaternary pump (G1311A), and UV detector
(G1314B). Instrumental control, data acquisition, and pro-
cessing were all carried out using ChemStation software
(Agilent Technologies, Wokingham, UK).
A Synergi Polar-RP 80 Å 250×4.6 mm column fitted
with a Synergi Polar-RP 80 Å guard column (Phenomenex,
Macclesfield, UK) was used for chromatographic separa-
tion. The column was kept at 40 °C, and the detection
absorption wavelength set at 254 nm. Strata X solid-phase
extraction (SPE) cartridges (30 mg ml−1) were purchased
from Phenomenex (Macclesfield, UK).
The mobile phase was adapted from a previous study
[21] and consisted of a gradient mix of phosphate buffer
(39 mM K2HPO4, 26 mM KH2PO4, and 10 mM TBAHS;
solution A) adjusted to pH 6.0 with orthophosphoric acid
and ACN (solution B) at concentrations that varied from
2 % to 30 % over the duration of the HPLC run as follows:
0 min (98 % solution A, 2 % solution B), 10 min (92 %
solution A, 8 % solution B), 20 min (70 % solution A, 30 %
solution B), 20.5 min (98 % solution A, 2 % solution B),
35 min (98 % solution A, 2 % solution B). The flow rate was
set at 1 ml min−1, and an injection volume of 100 μl was
used for all analyzed samples. The column was conditioned
for 15 min prior to running the first and subsequent samples,
by applying phosphate buffer in 2 % ACN to the column.
Samples were kept at room temperature in the autosampler
for no longer than 12-h before injection. Analyte stability
was tested and showed no significant degradation over 12-h
(not shown). To elute all remaining compounds from the column
and increase its lifetime, the column was washed at the end of
each sequence for 20 min using a gradient of ACN (2–50 %) in
phosphate buffer. All compounds were identified on the basis of
their retention time (Table 1).
Preparation of standard and working solutions
All solutions were assayed in 2 ml amber glass HPLC vials
(Chromacol, Welwyn Garden City, UK) with inserts if
necessary. Buffers were made up daily and kept at 4 °C
until required. Stock solutions containing all nucleotides and
nucleosides were prepared in dH2O at a concentration of
50 μg ml−1, and appropriate serial dilutions were made, to
the lowest limit of detection (LoD). Original stock solutions
were stable for up to 3 months when stored in the dark at
−20 °C. For each experiment, serial dilutions of all standard
analytes were freshly prepared from frozen stock (50μgml−1).
To obtain the standard curves necessary for determining
unknown sample concentrations for all compounds, standards
were separated in parallel with all experimental samples. To
ensure accuracy and precision of the method was maintained,
working standard solutions of all 12 nucleotides and nucleo-
sides were used to “spike” cell/urine media samples. Duplicate
injections were performed for all assays.
Cell buffer and patient urine samples
Immortalized M1 cells were used from passage 25 to 30 and
maintained in six-well plates in DMEM media supple-
mented with: FBS (5 %), penicillin (100 units ml−1), strep-
tomycin (100 μg ml−1), insulin (6.7 ng ml−1), transferrin
(5.5 μg ml−1), selenium (5.5 μg ml−1), and ethanolamine
(2 μg ml−1), in a humidified incubator at 37 °C and 5 %
CO2/95 % O2 atmosphere. Media was refreshed every 48 h,
and cells were passaged when confluent (approximately every
4 days). Experiments were only performed using confluent
cells. Cell media volume and buffer treatments were kept
constant at 1 ml well−1. In order to normalize nucleotide
release (nmol mg−1 protein), cells were lysed after experimen-
tation and the protein levels quantified. For comparison pur-
poses, cells were treated with either an isotonic physiological
buffer (in mM: 132.5 NaCl, 3.5 KCl, 1 CaCl2, 1 MgCl2,
Table 1 Analytical data for
nucleotide and nucleoside
detection. LoD and LoQ are
expressed in nanomolars (nM)
and picomoles (pmol) per 100 μl
of sample, in parenthesis. Data
are the mean of five separate
experiments (n05)
Analyte Retention time (min) Slope Intercept r2 LoD LoQ
ATP 21.8 1,219 0.89 0.9984 2.70 (0.27 pmol) 9.03 (0.90 pmol)
ADP 18.7 1,343 1.91 0.9996 2.67 (0.26 pmol) 8.91 (0.89 pmol)
AMP 12.3 1,978 1.52 0.9999 2.50 (0.24 pmol) 8.02 (0.80 pmol)
Ado 8.7 3,245 0.41 0.9962 0.89 (0.08 pmol) 2.97 (0.29 pmol)
GTP 20.5 1,340 1.40 0.9996 1.93 (0.19 pmol) 6.44 (0.64 pmol)
GDP 14.4 1,853 12.59 0.9971 1.44 (0.14 pmol) 4.83 (0.48 pmol)
GMP 7.7 2,124 12.08 0.9999 2.07 (0.20 pmol) 6.90 (0.69 pmol)
Gua 5.5 3,266 88.66 0.9993 1.73 (0.17 pmol) 5.76 (0.57 pmol)
UTP 20.8 687 0.88 0.9995 4.32 (0.43 pmol) 14.42 (1.44 pmol)
UDP 13.2 728 1.03 0.9998 4.56 (0.45 pmol) 15.22 (1.52 pmol)
UMP 6.7 1,544 11.10 0.9998 3.17 (0.31 pmol) 10.58 (1.05 pmol)
Uri 4.5 1,215 50.76 0.9880 4.23 (0.42 pmol) 14.13 (1.41 pmol)
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NaHCO3, 10HEPES, 5 glucose; pH 7.4) or a hypotonic buffer
(in mM: 72.5 NaCl, 3.5 KCl, 1 mM CaCl2, 1 MgCl2,
NaHCO3, 10 HEPES, 5 glucose; pH 7.4), to stimulate further
release of nucleotides and/or nucleosides. These experiments
were carried out by (1) removing the media, (2) adding either
an isotonic or hypotonic buffer onto the wells, and (3) imme-
diately removing and snap-freezing the buffer, to −80 °C until
further analysis. All steps were carried out with care to avoid
any mechanical disruption to cells.
With written consent, urine samples were obtained
from human patients diagnosed with OAB attending
the Whittington Hospital (UCL, London, UK) by trained
physicians. Appropriate asymptomatic non-OAB controls
were selected from university and hospital staff. Samples
were immediately snap-frozen and kept at −80 °C until the
time of processing. Immediately prior to HPLC analysis,
samples were thawed, sterile-filtered (0.22 μm), and
subjected to SPE as described below.
SPE treatment of urine samples
To remove proteins and polar contaminants from urine
samples, they were subjected to an optimised SPE procedure
[19]. Polymeric reversed-phase Strata-X SPE cartridges
(30 mg ml−1) and a 24-position vacuum manifold (Phenom-
enex, Macclesfield, UK) were utilized. Throughout, a low-
pressure vacuum (2–3 mmHg for approximately 2 min) was
used to collect all eluted fractions in separate HPLC vials.
Each cartridge was initially pre-conditioned with 1 ml
dH2O. The undiluted sample (1 ml) was loaded onto the
pre-conditioned SPE cartridges, vacuum applied, and the
resulting flow-through collected as fraction 1 (F1). A wash
solution (1 ml) containing 25 mM ethanolamine (pH 5) was
subsequently added and the resulting eluate collected as
fraction 2 (F2). Finally, to elute remaining nucleotides and
nucleosides, a solution (1 ml) of 30 % methanol in 25 mM
ethanolamine (pH 5) was flushed through the cartridge to
obtain fraction 3 (F3). Different percentages of different
analytes were eluted in all fractions, and therefore, all frac-
tions were subjected to full HPLC analysis. All fractions
were injected separately, and the sum of the results for all of
them was used to obtain the final total amount of nucleotides
and nucleosides present in the original urine samples. The
effect of SPE treatment on recovery rates was obtained by
comparing the levels of nucleotide and nucleoside standards
recovered in all three fractions, with and without SPE pre-
treatment. Urinary creatinine was measured according to the
manufacturer’s instructions using a modified Jaffe method.
Inhibition of nucleotidases in cell buffers
Cell buffers were immediately treated with perchloric acid
(HClO4) to inactivate/inhibit nucleotidase activity, as
previously described [23, 26]. Briefly, HClO4 (120 μl,
0.4 M) was added to each cell buffer sample (800 μl). The
sample was then neutralized with KOH (172 μl, 1 M)
and the pH adjusted to 7.0. Samples were centrifuged at
13,000 rpm for 5 min to remove precipitates, and the
supernatant was transferred into tubes and immediately
snap-frozen until further analysis.
Method validation
The method was validated for: specificity, linearity, LoD,
lower limit of quantification (LoQ), system precision,
accuracy, intermediate precision, and recovery rates after
SPE.
The specificity was assessed by analyzing endoge-
nous interferences within the samples and by running
chromatograms with single analytes versus chromato-
grams containing all analytes of interest. The linearity
was assessed by calibration of eight-point standard
curves in dH2O for all compounds, from 50 μg ml
−1 down
to their LoQ.
The LoD was defined as three times the signal-to-noise
ratio, whereas the LoQ was set at ten times the signal-to-
noise ratio [27]. System precision was tested by injecting the
same standard sample into the column six times. Six
different sets of urine samples and isotonic cell buffers were
used and spiked at two different concentrations (250 and
1,500 ng per 100 μl sample) to investigate the intermediate
precision and accuracy. The accuracy was calculated by
comparing the expected concentrations with the actual
measured concentrations of the samples spiked with all
12 nucleotides and nucleosides. The intermediate preci-
sion was assessed by determining the relative standard
deviation RSD %ð Þ ¼ SD=mean foundð Þ  100½  of the repli-
cate analyses.
Stability studies for all analytes were performed under
conditions comparable to those encountered during sample
preparation and HPLC analysis, i.e., standard analyte mixes
in dH2O were kept at room temperature in the autosampler.
Analyses were repeated every 12-h for a period of up to
36-h.
Statistical analysis
Unless otherwise stated, all values are expressed as mean ±
SEM (standard error of the mean). All experiments were
repeated at least three times, with each value representing
the average of duplicate injections. For statistical analysis,
unpaired t tests were used to assess for significant differ-
ences between experiments and appropriate controls.
Results were analyzed with Graph Pad Prism 5 (La Jolla,
California, USA), and values of P<0.05 were considered
statistically significant.
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Results and discussion
HPLC separation
A Synergi polar-RP column was chosen to separate various
nucleotides and nucleosides. Nucleosides consist of a
nitrogenous base and sugar, while nucleotides consist of a
nitrogenous base, sugar, and phosphate group. The phos-
phate group on the nucleotide makes the compound
extremely polar. The nitrogenous bases in the com-
pounds used here are all purines which are heterocyclic
aromatic organic compounds consisting of a pyrimidine
ring fused to an imidazole ring. The best column sepa-
ration of nucleosides and nucleotides depends upon the
column’s phase. A column that provides low hydropho-
bicity and a high polar and aromatic selectivity enhances
separation.
Two of the nucleosides analyzed, guanosine and adeno-
sine, are highly polar in nature and are, in essence, not
retained on reversed-phase columns by organic solvents.
This problem can be overcome by running these compounds
in very polar mobile phases, and, in this study, we used a
buffer containing an ACN gradient (2–30 %). The mobile
phase was also maintained at pH 6 to ensure all nucleotides
and nucleosides remained in their uncharged forms, there-
fore increasing their retention time. However, at this pH, the
lone pair of electrons on the nitrogen atoms may act as a
base and interact with the silanol group in the stationary
phase of the column to cause “peak tailing”. Hence, an ion-
pairing agent (TBAHS) was added to the mobile phase in
attempt to reduce this tailing for some of the nucleotides and
nucleosides (Fig. 1). Agents such as TBAHS have been
used in previous studies utilizing UV-coupled separation
methods [19, 21].
Figure 1 shows an HPLC chromatogram for the separa-
tion of a standard aqueous mixture (50 μg ml−1) of all
analytes of interest (ATP, ADP, AMP, Ado, GTP, GDP,
GMP, Gua, UTP, UDP, UMP, and Uri). The HPLC method
employed here provides a simple technique to simultaneous-
ly determine the concentration of all nucleotides and nucleo-
sides using UV detection at 254 nm. We identified all
analytes on the basis of their retention time (Table 1). Sep-
aration of other structurally related purine bases (e.g., uric
acid, hypoxanthines, xanthines) was not attempted in this
study. The total analysis time was 35 min per sample com-
prised of a column run time of 22 min and a post-run
stabilization time of approximately 13 min. Although
shorter stabilization periods have been reported in the liter-
ature [21], a time of less than 13 min resulted in substantial
overlap of the GTP/UTP and UDP/GDP peaks in our hands.
Despite this, 35 min is still substantially shorter than other
published methods that analyzed multiple compounds in a
single run (≥1 h) [20, 25, 28–30].
Development of the urine sample SPE treatment
Biological samples often present with high levels of protein
and polar contaminants, which makes the determination of
nucleotide and nucleoside concentration difficult. A stan-
dard approach for eliminating proteins is to precipitate with
organic solvents [31]. We attempted this by mixing equal
volumes of ACN and sample and then filtering out the
precipitates; this approach did not significantly improve
the shape of the chromatogram, likely due to interfering
polar compounds being retained in the samples. In other
studies, reversed-phase SPE columns were used to pre-treat
complex biological samples such as cerebrospinal fluid [19].
However, using Strata X SPE columns according to manu-
facturer’s recommendations, a high proportion of analytes
were retained leading to low recovery values. Consequently,
we optimized the protocol by pre-conditioned the columns
by first adding dH2O, after which samples were loaded, and
the flow-through collected as F1. Elution of nucleotides
and nucleosides was evaluated by addition of 25 mM
Column elution time (min)


































chromatogram of a standard
aqueous mixture of 12 nucleotides
and nucleosides (50 μg ml−1)
separated and analyzed using
ion-pair reversed-phase HPLC
coupled to a UV detector (set
at 254 nm). Identities of the
relevant peaks are: (1) Uri, (2)
Gua, (3) UMP, (4) GMP, (5)
Ado, (6) AMP, (7) UDP, (8)
GDP, (9) ADP, (10) GTP, (11)
UTP, (12) ATP
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ethanolamine at three different pH values: 5.0, 6.0, and 7.0.
The resulting elution fractions were collected as F2. All
remaining compounds were then eluted using 30 % metha-
nol in the different ethanolamine solutions (pH 5, 6, and 7),
constituting F3. The three fractions were injected into the
HPLC system separately and the results pooled to calculate
the total amount of nucleotides and nucleosides present in
the original samples.
As shown in Table 2, optimal results were obtained for
both F2 and F3 when using ethanolamine at pH 5.0.
Recovery values ranged from 98.8 % to 104.4 % with the
exception of Uri which yielded 130.8 %. Unusually high
yields may be explained by the presence of other low-
molecular-weight compounds remaining in the samples
and forming complexes with the nucleotides and nucleo-
sides to give a higher UV-absorbance than expected [19].
The recovery values for the other nucleotides and nucleo-
sides present suggest it is unlikely that Uri is co-eluting or
co-determining with other nucleotide/nucleoside analytes.
However, the small peak observed immediately ahead of
the Uri peak (see Fig. 1) is potentially contributing to the
unusually high yield obtained for this analyte. Hence, to
control for any inaccuracies, all final SPE yields were
normalized to correct for these values. This peak was
not further investigated. F1 and F2 contained different
proportions of nucleotides and nucleosides, whereas F3
primarily contained Ado (results not shown), and therefore
all three individually analyzed fractions were pooled into
one final value.
Method validation
The specificity of the method was tested for endogenous
interference from samples. Although urine samples pre-
sented interfering peaks and were first purified by SPE, cell
buffers did not, and hence, were analyzed directly by
HPLC-UV (as shown in Fig. 2).
Calibration curves were obtained by using linear regres-
sion analysis of eight-point concentration curves (not
shown). The regression parameters, including slope, inter-
cept, and correlation coefficient (r), are shown in Table 1.
The r values were good (0.9999 for AMP to 0.9880 for Uri),
and linearity was checked for the range of concentrations
from 50 μg ml−1 down to the LoQ of the respective nucleo-
tides and nucleosides. LoD values ranged from as low as
0.89 nM for Ado up to 4.56 nM of UDP (Table 1). LoQ
values were found to be from 2.97 nM for Ado up to
15.22 nM for UDP (Table 1). LoQ values established here
are substantially lower than those reported in previous stud-
ies using a coupled-column [32], or standard UV-coupled
HPLC [28, 32, 33]. Specifically, the values for ATP, ADP,
Ado, GTP, GDP, and GMP are one order of magnitude
lower than those of one recent publication [21]. Moreover,
although not all relevant nucleotides and nucleosides were
analyzed, a recent LC-MS-based study by Buescher and
colleagues reported similar LoQ values for ATP, ADP,
AMP, GTP, and GMP to those found here [34]. Additional
pre-treatment of samples (e.g., drying–resuspension or
lyophilization) could be beneficial in cases in which the
analytes of interest are below the LoQ of the technique
presented here.
To check the system’s precision, six replicate analyses of
the standards were carried out. The percentage RSD ranged
between 0.08 and 0.87 indicating satisfactory precision for
analysis [27].
The accuracy of the protocol was determined for each
analyte by performing recovery analysis of six cell buffer
samples independently spiked with two different concentra-
tions of standards containing all 12 nucleotides and nucleo-
sides (Fig. 2). As shown in Table 3, the accuracy varied
from 80.66 % up to 115.20 %, a satisfactory level for this
method. Moreover, the intermediate precision of the
method (1.22 % and 11.48 % RSD) was also found to
be satisfactory [27].
In order to simulate the sample preparation and auto-
sampler conditions, the stability of all nucleotides and
nucleosides was assessed by storing standard mixtures at
room temperature and then analyzing them at 12-h intervals
over a 36-h period. All compounds remained stable for up to
12-h in these conditions, whereas some nucleotides (i.e.,
ATP, AMP, and GTP) showed significant degradation or
higher levels (i.e., UTP, UDP, GMP, and Gua) after 12-
and 24-h intervals (not shown). This indicates that samples
Table 2 Total recovery of nucleotides and nucleosides from urine
samples spiked with a standard mixture of all compounds of interest







ATP 100.2 100.9 99.6
ADP 99.9 104.0 100.2
AMP 98.8 100.8 99.1
Ado 99.4 102.2 99.9
GTP 100.5 105.6 106.3
GDP 104.4 108.5 111.2
GMP 99.2 101.4 98.8
Gua 100.4 102.7 102.4
UTP 103.8 106.0 105.5
UDP 100.8 103.1 102.4
UMP 99.0 100.9 80.7
Uri 130.8 132.4 131.9
Data shown summarizes the overall recovery achieved in all three
pooled fractions (F1, 2, and 3). The recovery of analytes in F2 and
F3 was tested using 25 mM ethanolamine at three different pH values
(5.0, 6.0, 7.0) and the results pooled together with fraction 1. Data are
the mean of three separate experiments (n03)
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should not be left at room temperature, or in the autosam-
pler, for longer than 12-h prior to analysis. If this cannot be
achieved in future studies, it is recommended that a refrig-
erated autosampler be employed.
Inhibition of nucleotidases
Some biological fluids and samples may contain membrane-
bound and/or soluble nucleotidases [35]. To prevent enzy-
matic degradation of nucleotides and nucleosides, nucleo-
tidase activity was inhibited by acid-treatment [23, 26]. To
restore a neutral pH to samples, the HClO4 was neutralized
with KOH, producing a precipitate that needed to be re-
moved from the samples by centrifugation. It is likely that,
despite our efforts to completely remove these precipitates,
they continued to form over time as compounds adsorbed to
the remaining perchlorate [36]. It was noted that, for some
analytes, this treatment increased the area under the peak
and modified the retention times, and hence, we normalized
for these effects by also treating the standards with HClO4/
KOH. Alternative methods for inhibiting nucleotidases are






























































Fig. 2 Representative HPLC-UV
chromatograms of (a) normal
hypotonic cell buffer sample
and (b) hypotonic cell culture
buffer sample spiked with a
standard mixture of all analytes
of interest (1,500 ng). Identities
of the relevant peaks are: (1) Uri,
(2) Gua, (3) UMP, (4) GMP, (5)
Ado, (6) AMP, (7) UDP, (8)
GDP, (9) ADP, (10) GTP, (11)
UTP, (12) ATP
Table 3 Accuracy and intermediate precision of the HPLC-UV
separation method
Compound Spiked (250 ng) Spiked (1500 ng)
Accuracy (%) RSD (%) Accuracy (%) RSD (%)
ATP 93.32 3.15 93.32 2.23
ADP 92.39 10.67 93.42 5.33
AMP 92.87 4.37 93.31 1.30
Ado 97.35 2.47 93.34 1.93
GTP 97.10 11.48 87.33 9.89
GDP 102.58 3.22 96.52 2.70
GMP 100.48 1.77 95.32 1.89
Gua 115.20 5.60 85.24 2.82
UTP 92.24 11.48 95.84 5.75
UDP 112.37 1.22 99.43 2.76
UMP 100.76 1.67 95.96 1.84
Uri 80.66 3.10 82.96 5.91
Isotonic cell buffer samples were spiked with either 250 or 1,500 ng of
a standard mixture of all nucleotides and nucleosides of interest. For
further information, see the “Results and discussion.” Data are the
mean of six separate experiments (n06)
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been shown to rapidly and irreversibly inactivate nucleoti-
dases [37] and several ectonucleotidase inhibitors, including
ARL67156 are available [38]. Unfortunately, the relatively
high cost of such inhibitors precludes their use in large-scale
studies. Heat inactivation has been used to treat tissue
culture samples, as adenosine nucleotides can withstand the
high temperatures required to inactivate nucleotidases [39].
Analysis of in vitro samples: nucleotide and nucleoside
release from a renal cell line
Epithelial cells are known to release adenosine and uridine
nucleotides under both basal and stimulated conditions.
Tatur and colleagues used an ion-pair reversed-phased
HPLC technique to quantify extracellular nucleotides and
nucleosides released from A549 lung epithelial cells [40].
They showed ATP, ADP, UTP, and UDP release were all
increased following hypotonic shock, with no changes in
AMP and Ado levels. Primary cultures of human renal
epithelia (proximal tubule, mixed cortical and polycystic
kidney cells) have also been shown to release ATP and other
nucleotides, including diadenosine pentaphosphate and hex-
aphosphate after hypotonic stimulation [41, 42]. Moreover,
Schwiebert et al. reported the release of low concentrations
(nanomolars to picomolars) of ATP from native cortical
collecting duct (CCD) cells that increased after hypotonic
stimulation [43]. Once normalized to cellular protein levels
(a measure of cell number), our results indicated that all 12
nucleotides and nucleosides were present in isotonic and
hypotonic buffers that had been in contact with the cells
(Table 4). To ensure that the differences in levels of
nucleotides and nucleosides following stimulation were
unlikely to originate from degradation pathways, but from
immediate release from cells, nucleotidases were inhibited
by acid-treating samples immediately prior to analysis. Cell
viability was confirmed by trypan blue exclusion staining
and morphological assessment (data not shown).
To the best of our knowledge, our study is the first to
simultaneously measure an increase in ATP, AMP, Ado,
GMP, Gua, and UMP and a decrease in GDP, following
hypotonic challenge of a renal cell line. No changes were
observed in ADP, GTP, UTP, UDP, and Uri levels (Table 4).
In general agreement with previous observations of low
nanomolar release in basal conditions [43], the ATP con-
centration, prior to normalization to the protein level, ranged
from 110 nM under basal (isotonic) conditions to 370 nM
after hypotonic stimulation. However, these values are low-
er than those reported in some studies (0.5–2 μM; [42]).
This discrepancy may be explained by differences in cell
type used, cell numbers, or the degree of increase in hypo-
tonicity. All publications concur in reporting higher levels of
ATP release following hypotonic stimulation, a condition
likened to the process of stretch in the lumen of the nephron.
Due to the complexity and wide distribution of P1Rs and
P2Rs in the kidney, the physiological significance of in-
creased levels of nucleotides and nucleosides remains large-
ly undefined. A recent review highlighted the implications
for regulation of transport mechanisms for sodium, potassi-
um, and other ions [44]. Others have proposed that the renal
hemodynamic function and microvasculature are also regu-
lated by P1Rs and P2Rs [6, 7]. This HPLC technique will
Table 4 Nucleotide and nucleoside release from M1 renal cells under
isotonic and hypotonic buffer conditions













Data are expressed as nM µg−1 protein and are means ± SEM
(n018)
a Values that are significantly different from isotonic buffer (unpaired t
test; P<0.05). For further information, see the “Results and discussion”
Table 5 Levels of nucleotides and nucleosides in urine from OAB
patients and asymptomatic non-OAB controls













Data are expressed as pM mg−1 creatinine dL−1 and are means ± SEM
(n033 for OAB; n011 for non-OAB controls)
a Values that are significantly different from asymptomatic non-OAB
control (unpaired t test; P<0.05). For further information, see the
“Results and discussion”
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facilitate further in vitro and in vivo studies into the role of
multiple nucleotides and nucleosides in kidney function.
Analysis of biological samples: urine from OAB patients
Historically, nucleotide analysis of the urine of cancer
patients has shown differences in levels of some purines
and pyrimidines in comparison to those of healthy controls
[30, 45–47]. These compounds may originate from either
increased turnover of different types of RNA [47], or from
extracellular release from the urinary tract [48–51]. Altered
nucleotide and/or nucleoside signalling is also implicated in
several other bladder diseases, including OAB [10–14]. In
this study, we use our optimized HPLC-UV method to
investigate: (1) the viability of detecting all 12 compounds
of interest in the urine of OAB and asymptomatic non-OAB
control patients and (2) whether urinary ATP and other
nucleotides and/or nucleosides levels is altered in the cohort
of OAB patients. All analyte levels were normalized to
urinary creatinine levels to account for differences in urine
concentration [30]. As shown in Table 5, all 12 nucleotides
and nucleosides were detected in the urine of OAB patients
and controls. However, large variations in some of the
analytes were observed between individuals, even within
the same sample group. A similar level of variation has
been reported in the levels of other urinary nucleotides
and nucleosides from cancer patients [45]. Despite an
apparent trend towards higher levels of urinary AMP,
GTP, GMP, UDP, and Uri in OAB patients, the only
significant changes in the urine of these patients were
an increase in Ado, and a decrease in UMP (P<0.05; n≥11).
The variation within patient groups is most likely affect-
ing the significance levels, and thus larger groups will be
required to increase the statistical power of further studies.
P1Rs are widely expressed throughout all layers of the uro-
thelium, and while their role remains largely unexplored, a
previous study suggested P1Rsmodulate exocytosis in umbrella
cells [52]. We hypothesize that increased urinary levels of Ado
in the OAB group could trigger exocytotic mechanisms, which
in turn may cause the exacerbated release of ATP from bladder
urothelial cells. This increased urothelial ATP release would
ultimately activate P2Rs in sensory afferents, leading to hyper-
stimulation and the symptoms of OAB [53]. Understanding the
effect of decreased UMP and other extracellular guanosine and
uridine nucleotides in the urinary tract will require further
investigation.
Practical application
The method described in this study is rapid and direct, and
readily performed using standard HPLC apparatus. Sample
preparation and HPLC fractionation and analysis can all be
performed in 12-h or less at room temperature without concern
for nucleotide/nucleoside degradation, and hence, this method
has the potential to be applied in wide variety of research and
clinical environments. Where ready access to HPLC is not
available, this technique offers a clear opportunity for cost-
effective (<£5 per sample; see Online resource 1 in Electronic
supplementary material) and focused collaborative research be-
tween clinical facilities and more chemically/pharmacologically
oriented laboratories, such as our own.
Conclusion
In this study, we describe a HPLC-UV method that permits
simultaneous quantification of 12 different nucleotides and
nucleosides in in vitro and biological samples. Validation of
the method indicates it has good specificity, linearity, LoQ,
LoD, system precision, accuracy, and intermediate precision.
The sensitivity of the method is similar to, or better than,
previous reports, yet the number of analytes per run are
significantly higher than similar systems using the same de-
tector and provides shorter run times. The protocol was suc-
cessfully used to detect differences in low levels of
nucleotides and nucleosides in all samples. Moreover, this
method can be further adapted to detect other relevant endog-
enous nucleotides and nucleosides of interest. This analytical
technique may not only contribute to our understanding of the
physiology and pathophysiology of the lower urinary tract but
also prove particularly useful in studying nucleotide and nu-
cleoside levels in other organs or systems.
Acknowledgments The Wellcome Trust, The Bloomsbury Consor-
tium (University of London) and St. Peter’s Trust for Kidney, Bladder,
and Prostate research supported this work.
Conflict of interest Scott Wildman and James Malone-Lee received
support from Pfizer Ltd., during 2010/2011.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Bodin P, Burnstock G (2001) Purinergic signalling: ATP release.
Neurochem Res 26:959–969
2. Corriden R, Insel PA (2010) Basal release of ATP: an autocrine-
paracrine mechanism for cell regulation. Sci Signal 3:re1
3. Praetorius HA, Leipziger J (2009) ATP release from non-excitable
cells. Purinergic Signal 5:433–446
4. Burnstock G (2006) Purinergic signalling. Br J Pharmacol 147
(Suppl 1):S172–S181
5. Burnstock G (2007) Physiology and pathophysiology of purinergic
neurotransmission. Physiol Rev 87:659–797
Purinergic Signalling (2012) 8:741–751 749
6. Crawford C, Kennedy-Lydon TM, Callaghan H, Sprott C,
Simmons RL, Sawbridge L, Syme HM, Unwin RJ, Wildman SS,
Peppiatt-Wildman CM (2011) Extracellular nucleotides affect
pericyte-mediated regulation of rat in situ vasa recta diameter.
Acta Physiol (Oxf) 202:241–251
7. Inscho EW (2009) ATP, P2 receptors and the renal microcircula-
tion. Purinergic Signal 5:447–460
8. Praetorius HA, Leipziger J (2010) Intrarenal purinergic signaling
in the control of renal tubular transport. Annu Rev Physiol
72:377–393
9. Burnstock G (2006) Pathophysiology and therapeutic potential of
purinergic signaling. Pharmacol Rev 58:58–86
10. Sugaya K, Nishijima S, Kadekawa K, Miyazato M, Mukouyama H
(2009) Relationship between lower urinary tract symptoms and
urinary ATP in patients with benign prostatic hyperplasia or
overactive bladder. Biomed Res 30:287–294
11. Cheng Y, Mansfield KJ, Allen W, Walsh CA, Burcher E, Moore
KH (2010) Does adenosine triphosphate released into voided
urodynamic fluid contribute to urgency signaling in women with
bladder dysfunction? J Urol 183:1082–1086
12. Kumar V, Chapple CR, Rosario D, Tophill PR, Chess-Williams R
(2010) In vitro release of adenosine triphosphate from the
urothelium of human bladders with detrusor overactivity, both
neurogenic and idiopathic. Eur Urol 57:1087–1092
13. Sun Y, Chai TC, Sun Y, Keay S, De Deyne PG, Chai TC (2006)
Augmented extracellular ATP signaling in bladder urothelial cells
from patients with interstitial cystitis. Am J Physiol Cell Physiol
290:C27–C34
14. Sun Y, Keay S, De Deyne PG, Chai TC (2001) Augmented stretch
activated adenosine triphosphate release from bladder uroepithelial
cells in patients with interstitial cystitis. J Urol 166:1951–1956
15. Gever JR, Cockayne DA, Dillon MP, Burnstock G, Ford AP
(2006) Pharmacology of P2X channels. Pflugers Arch 452:513–537
16. von Kugelgen I (2006) Pharmacological profiles of cloned
mammalian P2Y-receptor subtypes. Pharmacol Ther 110:415–432
17. von Kugelgen I, Wetter A (2000) Molecular pharmacology of P2Y-
receptors. Naunyn Schmiedebergs Arch Pharmacol 362:310–323
18. Neufeld HA, Towner RD, Pace J (1975) A rapid method for
determining ATP by the firefly luciferin-luciferase system.
Experientia 31:391–392
19. Czarnecka J, Cieslak M, Michal K (2005) Application of solid
phase extraction and high-performance liquid chromatography to
qualitative and quantitative analysis of nucleotides and nucleosides
in human cerebrospinal fluid. J Chromatogr B Anal Technol
Biomed Life Sci 822:85–90
20. Gill BD, Indyk HE (2007) Development and application of a liquid
chromatographic method for analysis of nucleotides and nucleo-
sides in milk and infant formulas. Int Dairy J 17:596–605
21. Zur NS, Eason R, Doney AS, Frenguelli BG (2009) An ion-pair
reversed-phase HPLC method for determination of fresh tissue
adenine nucleotides avoiding freeze–thaw degradation of ATP.
Anal Biochem 388:108–114
22. Cordell RL, Hill SJ, Ortori CA, Barrett DA (2008) Quantitative
profiling of nucleotides and related phosphate-containing metabo-
lites in cultured mammalian cells by liquid chromatography
tandem electrospray mass spectrometry. J Chromatogr B Anal
Technol Biomed Life Sci 871:115–124
23. Vinas P, Campillo N, Melgarejo GF, Vasallo MI, Lopez-Garcia I,
Hernandez-Cordoba M (2010) Ion-pair high-performance liquid
chromatography with diode array detection coupled to dual
electrospray atmospheric pressure chemical ionization time-of-
flight mass spectrometry for the determination of nucleotides in
baby foods. J Chromatogr A 1217:5197–5203
24. Yamaoka N, Kudo Y, Inazawa K, Inagawa S, Yasuda M, Mawatari
K, Nakagomi K, Kaneko K (2010) Simultaneous determination of
nucleosides and nucleotides in dietary foods and beverages using
ion-pairing liquid chromatography-electrospray ionization-mass
spectrometry. J Chromatogr B Anal Technol Biomed Life Sci
878:2054–2060
25. Yang FQ, Li DQ, Feng K, Hu DJ, Li SP (2010) Determination of
nucleotides, nucleosides and their transformation products in
Cordyceps by ion-pairing reversed-phase liquid chromatography-
mass spectrometry. J Chromatogr A 1217:5501–5510
26. Manfredi G, Yang L, Gajewski CD, Mattiazzi M (2002) Measure-
ments of ATP in mammalian cells. Methods 26:317–326
27. Committee for Proprietary Medicinal Products (1995) Validation
of analytical procedures: text and methodology-Q2(R1). Interna-
tional Conference of Harmonisation CPMP/ICH/381/95: 1–13
28. Cichna M, Raab M, Daxecker H, Griesmacher A, Muller MM,
Markl P (2003) Determination of fifteen nucleotides in cultured
human mononuclear blood and umbilical vein endothelial cells by
solvent generated ion-pair chromatography. J Chromatogr B Anal
Technol Biomed Life Sci 787:381–391
29. Katayama M, Matsuda Y, Shimokawa K, Tanabe S, Kaneko S,
Hara I, Sato H (2001) Simultaneous determination of six adenyl
purines in human plasma by high-performance liquid chromatog-
raphy with fluorescence derivatization. J Chromatogr B: Biomed
Sci Appl 760:159–163
30. Xu G, Di Stefano C, Liebich HM, Zhang Y, Lu P (1999) Reversed-
phase high-performance liquid chromatographic investigation of
urinary normal and modified nucleosides of cancer patients. J
Chromatogr B: Biomed Sci Appl 732:307–313
31. Mathies JC, Austin MA (1980) Modified acetonitrile protein-
precipitation method of sample preparation for drug assay by
liquid chromatography. Clin Chem 26:1760
32. Zheng Y, Xu G, Yang J, Zhao X, Pang T, Kong H (2005)
Determination of urinary nucleosides by direct injection and
coupled-column high-performance liquid chromatography. J
Chromatogr B Anal Technol Biomed Life Sci 819:85–90
33. Svensson JO, Jonzon B (1990) Determination of adenosine and
cyclic adenosine monophosphate in urine using solid-phase
extraction and high-performance liquid chromatography with
fluorimetric detection. J Chromatogr 529:437–441
34. Buescher JM, Moco S, Sauer U, Zamboni N (2010) Ultrahigh
performance liquid chromatography-tandem mass spectrometry
method for fast and robust quantification of anionic and aromatic
metabolites. Anal Chem 82:4403–4412
35. Todorov LD, Mihaylova-Todorova S, Westfall TD, Sneddon P,
Kennedy C, Bjur RA, Westfall DP (1997) Neuronal release of
soluble nucleotidases and their role in neurotransmitter inactivation.
Nature 387:76–79
36. Wiener S, Wiener R, Urivetzky M, Meilman E (1974) Coprecipi-
tation of ATP with potassium perchlorate: the effect of the firefly
enzyme assay of ATP in tissue and blood. Anal Biochem 59:489–500
37. Schneider DR, Felt BT, Rappaport MS, Goldman H (1982)
Development and use of a nonrestraining waveguide chamber for
rapid microwave radiation killing of the mouse and neonate rat. J
Pharmacol Methods 8:265–274
38. Levesque SA, Lavoie EG, Lecka J, Bigonnesse F, Sevigny J
(2007) Specificity of the ecto-ATPase inhibitor ARL 67156 on
human and mouse ectonucleotidases. Br J Pharmacol 152:141–150
39. Ozer N, AksoyY, Ogus IH (2000) New sample preparationmethod for
the capillary electrophoretic determination of adenylate energy charge
in human erythrocytes. J Biochem Biophys Methods 45:141–146
40. Tatur S, Kreda S, Lazarowski E, Grygorczyk R (2008) Calcium-
dependent release of adenosine and uridine nucleotides from A549
cells. Purinergic Signal 4:139–146
41. Jankowski V, Karadogan S, Vanholder R, Nofer JR, Herget-
Rosenthal S, van der Giet M, Tolle M, Tran TN, Zidek W,
Jankowski J (2007) Paracrine stimulation of vascular smooth
muscle proliferation by diadenosine polyphosphates released from
proximal tubule epithelial cells. Kidney Int 71:994–1000
750 Purinergic Signalling (2012) 8:741–751
42. Wilson PD, Hovater JS, Casey CC, Fortenberry JA, Schwiebert EM
(1999) ATP release mechanisms in primary cultures of epithelia derived
from the cysts of polycystic kidneys. J Am Soc Nephrol 10:218–229
43. Schwiebert EM, Kishore BK (2001) Extracellular nucleotide
signaling along the renal epithelium. Am J Physiol Ren Physiol
280:F945–F963
44. Bailey MA, Shirley DG (2009) Effects of extracellular nucleotides
on renal tubular solute transport. Purinergic Signal 5:473–480
45. Kim KR, La S, Kim A, Kim JH, Liebich HM (2001) Capillary
electrophoretic profiling and pattern recognition analysis of urinary
nucleosides from uterine myoma and cervical cancer patients. J
Chromatogr B: Biomed Sci Appl 754:97–106
46. Liebich HM, Di Stefano C, Wixforth A, Schmid HR (1997)
Quantitation of urinary nucleosides by high-performance liquid
chromatography. J Chromatogr A 763:193–197
47. Schram KH (1998) Urinary nucleosides. Mass Spectrom Rev
17:131–251
48. Calvert RC, Thompson CS, Burnstock G (2008) ATP release from
the human ureter on distension and P2X(3) receptor expression on
suburothelial sensory nerves. Purinergic Signal 4:377–381
49. Ferguson DR, Kennedy I, Burton TJ (1997) ATP is released from
rabbit urinary bladder epithelial cells by hydrostatic pressure
changes—a possible sensory mechanism? J Physiol 505(Pt
2):503–511
50. Inscho EW (2001) P2 receptors in regulation of renal microvascular
function. Am J Physiol Ren Physiol 280:F927–F944
51. Rump LC, Bohmann C, Schwertfeger E, Krumme B, von
Kügelgen I, Schollmeyer P (1996) Extracellular ATP in the
human kidney: mode of release and vascular effects. J Auton
Pharmacol 16:371–375
52. Yu W, Zacharia LC, Jackson EK, Apodaca G (2006) Adenosine
receptor expression and function in bladder uroepithelium. Am J
Physiol Cell Physiol 291:C254–C265
53. Birder LA (2010) Urothelial signaling. Auton Neurosci 153:33–40
Purinergic Signalling (2012) 8:741–751 751
